Dyne Therapeutics Statistics
Total Valuation
DYN has a market cap or net worth of $1.43 billion. The enterprise value is $775.76 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DYN has 113.67 million shares outstanding. The number of shares has increased by 53.90% in one year.
| Current Share Class | 113.67M |
| Shares Outstanding | 113.67M |
| Shares Change (YoY) | +53.90% |
| Shares Change (QoQ) | +7.78% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 87.05% |
| Float | 97.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.94 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.35, with a Debt / Equity ratio of 0.03.
| Current Ratio | 20.35 |
| Quick Ratio | 20.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.01% and return on invested capital (ROIC) is -41.47%.
| Return on Equity (ROE) | -64.01% |
| Return on Assets (ROA) | -39.92% |
| Return on Invested Capital (ROIC) | -41.47% |
| Return on Capital Employed (ROCE) | -57.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.92M |
| Employee Count | 191 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.69% in the last 52 weeks. The beta is 1.19, so DYN's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -51.69% |
| 50-Day Moving Average | 10.65 |
| 200-Day Moving Average | 24.52 |
| Relative Strength Index (RSI) | 61.71 |
| Average Volume (20 Days) | 3,107,262 |
Short Selling Information
The latest short interest is 14.86 million, so 13.07% of the outstanding shares have been sold short.
| Short Interest | 14.86M |
| Short Previous Month | 15.27M |
| Short % of Shares Out | 13.07% |
| Short % of Float | 15.24% |
| Short Ratio (days to cover) | 5.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -397.10M |
| Pretax Income | -257.40M |
| Net Income | -367.13M |
| EBITDA | -395.31M |
| EBIT | -397.10M |
| Earnings Per Share (EPS) | -$3.62 |
Full Income StatementBalance Sheet
The company has $677.49 million in cash and $23.33 million in debt, giving a net cash position of $654.16 million or $5.76 per share.
| Cash & Cash Equivalents | 677.49M |
| Total Debt | 23.33M |
| Net Cash | 654.16M |
| Net Cash Per Share | $5.76 |
| Equity (Book Value) | 668.97M |
| Book Value Per Share | 5.89 |
| Working Capital | 655.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$319.73 million and capital expenditures -$3.17 million, giving a free cash flow of -$322.89 million.
| Operating Cash Flow | -319.73M |
| Capital Expenditures | -3.17M |
| Free Cash Flow | -322.89M |
| FCF Per Share | -$2.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |